Clinical Challenge: Selecting the Optimal Therapy for Individual Patients

The Need: A clinical tool that provides practice-changing genomic information for personalizing breast cancer treatment.

Research has shown that not all women with early-stage invasive breast cancer benefit from chemotherapy1. Chemotherapy BenefitsMoreover, traditional clinical and pathologic factors alone, such as patient age, tumor size and tumor grade, are unable to identify those patients at the greatest risk of recurrence, nor can they identify those patients who will respond to chemotherapy. Therefore, there is a potential for the overtreatment of early-stage breast cancer, with all of its associated side effects, risks and costs.


The Solution: A test that can precisely and accurately assess risk of recurrence and identify those patients most likely to benefit from chemotherapy.

The Oncotype DX® Breast Recurrence Score™ was developed to meet this clinical challenge. This unique genomic test:

  • Is the only genomic test validated to predict adjuvant therapy benefit in patients with ER+, HER2-negative, early-stage invasive breast cancer
  • Provides an individualized and quantitative risk assessment that identifies the patient’s 10-year risk of distant recurrence
  • Delivers information beyond clinical and pathologic features
  • Is supported by data from studies with over 9,000 patients2-4
  • Is included in major clinical guidelines for chemotherapy decision-making
  • Has potentially helped thousands of patients around the globe avoid chemotherapy and its side effects5


Michael Alvarado MD, Director of Breast Surgery Oncology Fellowship University of California San Francisco and Jay K. Harness MD, Medical Director at discuss how the Breast Recurrence Score has changed treatment decisions for women with early-stage invasive breast cancer.



1. Peto et al. Lancet. 2012.
2. Levine et al. ASCO 2014.
3. Burke et al. EBCC 2014.
4. Vacirca et al. ASCO 2013.
5. Data on file. Genomic Health, Inc., 2014.
Next: Rigorous Development